Obinutuzumab for refractory minimal change disease in obese patients: a case series - Summary - MDSpire

Obinutuzumab for refractory minimal change disease in obese patients: a case series

  • By

  • Dandan Xue

  • Xiaofen Ma

  • Xiang Li

  • Yiming Zhang

  • Bing Xue

  • May 14, 2026

  • 0 min

Share

Objective:

Consider adding the significance of evaluating obinutuzumab in this specific patient population.

Key Findings:
  • Add context on the implications of sustained remission and the need for further studies.
Interpretation:

Make a clearer connection between the findings and the limitations discussed.

Limitations:
  • Expand on potential biases or confounding factors that may affect the results.
Conclusion:

Reiterate the necessity for further research to validate findings.

Original Source(s)

Obinutuzumab for refractory minimal change disease in obese patients: a case series

  • by Dandan Xue, Xiaofen Ma, Xiang Li, Yiming Zhang, Bing Xue

  • May 14, 2026

Related Content

Severe maternal morbidity in patients of advanced maternal age with and without metabolic syndrome

Child Opportunity Index and Prevalence of Obesity and Hypertension in Adolescents with Congenital Heart Disease

The interplay of maturity-onset diabetes of the young, obesity, uncontrolled hypertension, and cannabinoid hyperemesis in the progression to end-stage renal disease: a case report